1. Jordan WM. Pulmonary embolism. Lancet. 1961;2:1146–1147.
2. Boyce J, Fawcett JW, Noall EWP. Coronary thrombosis and Conovid. Lancet 1963; 1: 111.
3. Daly E, Vessey MP, Hawkins MM et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–80.
4. Jick H, Derby LE, Wald Myers M et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–3.
5. Grodstein F, Stampfer MJ, Goldhaber SZ et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983–7.
6. The Coronary Drug Project Research Group. The Coronary Drug Project: findings leading to discontinuation of the 2.5-mg day estrogen group. JAMA 1973; 226: 652–7.
7. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997; 47: 337–42.
8. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593–6.
9. World Health Organization. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1582–8.
10. Jick H, Jick SS, Gurewich V et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93.
11. Brandjes DP, BЯller HR, Heijboer H et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759–62.
12. Virchow R. Phlogose und Thrombose im Gef__system. In: Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt, Germany: Staatsdruckerei; 1856.
13. Records Unit and Research Advisory Service of the Royal College of General Practitioners. Oral contraception and thrombo-embolic disease. J R Coll Gen Pract 1967; 13: 267–79.
14. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. BMJ 1968; 1: 199–205.
15. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. BMJ 1969; 2: 651–7.
16. Sartwell PE, Masi AT, Arthes FG et al. Thromboembolism and oral contraceptives: an epidemiological case-control study. Am J Epidemiol 1969; 90: 365–80.
17. Boston Collaborative Drug Surveillance Program. Oral contraceptives and venous thromboembolic disease, surgically confirmed gall bladder disease and breast tumours. Lancet 1973; 1: 1399–404.
18. Porter JB. Oral contraceptives and nonfatal vascular disease: recent experience. Obstet Gynecol 1982; 59: 299–302.
19. Royal College of General Practitioners' Oral Contraception Study. Oral contraceptives, venous thrombosis, and varicose veins. J R Coll Gen Pract 1978; 28: 393–9.
20. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ 1986; 292: 526.
21. Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med 1995; 238: 31–7.
22. Lensing AW, Prandoni P, Brandjes D et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med 1989; 320: 342–5.
23. Huisman MV, Buller HR, Ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients: the Amsterdam General Practitioner Study. N Engl J Med 1986; 314: 823–8.
24. Stolley PD, Tonascia JA, Tockman MS et al. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol 1975; 102: 197–208.
25. Vandenbroucke JP, Koster T, Bri_t E et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453–7.
26. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol 1992; 21: 48–52.
27. World Health Organization. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre casecontrol study: World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1575–82.
28. Farmer RDT, Preston TD. The risk of venous thromboembolism associated with low-oestrogen oral contraceptives. J Obstet Gynecol 1995; 15: 195–200.
29. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000; 321: 1190–5.
30. Realini JP, Encarnacion CE, Chintapalli KN, Rees CR. Oral contraceptives and venous thromboembolism: a case-control study designed to minimize detection bias. J Am Board Fam Pract 1997; 10: 315–21.
31. Bloemenkamp KWM, Rosendaal FR, B_ller HR et ak. Risk of venous thrombosis with use of
current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999; 159: 65–70.
32. Gerstman BB, Piper JM, Tomita DK et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 32–7.
33. Spitzer WO, Lewis MA, Heinemann LA et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study: Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312: 83–8.
34. Bennet L, Odeberg H. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism. J Intern Med 1998; 244: 27–32.
35. Andersen BS, Olsen J, Nielsen GL et al. Third generation oral contraceptives and heritable thrombophilia as risk factors for non-fatal venous thromboembolism. Thromb Haemost 1998; 79: 28–31.
36. Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999; 59: 79–83.
37. Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354: 127–8.
38. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 700–3.
39. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a case-control study. Contraception 1998; 57: 291–301.
40. Farmer RD, Lawrenson RA, Thompson CR et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83–8.
41. Farmer RD, Todd JC, MacRae KD et al. Oral contraception was not associated with venous thromboembolic disease in recent study. BMJ 1998; 316: 1090–1.
42. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323: 131–4.
43. Spitzer WO. Thromboembolism and the pill: the saga must end. Hum Reprod 1998; 13: 1117–8.
44. Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. The pill and venous thromboembolism: a disarray of several layers of debate. Hum Reprod 1998; 13: 1119–20.
45. Spitzer WO. Balanced view of risks of oral contraceptive. Lancet 1997; 350: 1566–7.
46. Meirik O. Risks of oral contraceptives. Lancet 1998; 351: 521.
47. Lidegaard _. Oral contraceptives and venous thromboembolism: an epidemiological review. Eur J Contracept Reprod Health Care 1996; 1: 13–20.
48. Cramer DW. Safety of combined oral contraceptive pills. Lancet 1996; 347: 546–8.
49. Suissa S, Blais L, Spitzer WO et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141–6.
50. Lewis MA, Heinemann LA, MacRae KD et al. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research: the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 1996; 54: 5–13.
51. Farmer RD, Williams TJ, Simpson EL, Nightingale AL. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of general practice research database. BMJ 2000; 321: 477–9.
52. Todd J, Lawrenson R, Farmer RD et al. Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database. Hum Reprod 1999; 14: 1500–5.
53. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 1997; 177: 887–91.
54. Walker AM. Newer oral contraceptives and the risk of venous thromboembolism. Contraception 1998; 57: 169–81.
55. Farley TMM, Meirik O, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. Hum Reprod Update 1999; 5: 721–35.
56. Vandenbroucke JP, Rosing J, Bloemenkamp KW et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527–35.
57. World Health Organization. Cardiovascular Disease and Steroid Hormone Contraception: Report of a WHO Scientific Group. Geneva, Switzerland: World Health Organization; 1998. WHO Technical Report Series, No. 877.
58. Rosing J, Tans G, Nicolaes GA et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233–8.